Voir le texte source

Significantly more than six million people worldwide, including one million in america, live with Parkinson's disease-a persistent, degenerative, neurological condition that's indicated by symptoms that an average of progress from mild tremors to major physical incapacitation. Discover extra resources on this affiliated paper by clicking  [http://www.visresearch.org/clinical-research/center-optimization-analytics lymphoma investigator] . To get other interpretations, people may have a look at:  [http://www.visresearch.org/clinical-research/center-optimization-analytics my parkinson's trials] . Despite small advances in pharmaceutical and surgical therapies, there's no known treatment for Parkinson's. Be taught more on this related web resource by clicking  [http://www.visresearch.org/clinical-research/center-optimization-analytics lymphoma research] . The most useful expect obtaining one, say experts in-the field, is through clinical trials. Therein lies the problem. Although just about all (over 96 percent) of the physicians in the Usa who treat people with Parkinson's disease concur that clinical trials are necessary to find better therapies for the disease, many physicians have not known a to a clinical trial. These are among the features of the recent study commissioned by Advancing Parkinson's Therapies (APT), a collaborative effort spearheaded by leading Parkinson's companies. The survey also found that, among Parkinson's patients, 40 percent cite support groups and 27 percent cite others with the condition whilst the most frequent sources of information regarding clinical trials. Meanwhile, only 11 percent of people get data from their doctors. Currently, less than 1 percent of men and women with Parkinson's are participating in clinical research. This is far short of the amount that scientists anticipate will be needed for clinical studies on the next two to three years, including studies of treatments to slow or stop disease progression and to improve symptoms such as tremors. This difference might lead to serious delays in-the option of new remedies. Information Boundaries Lack of sufficient information about clinical trials was recognized as an obstacle to clinical trial enrollment. Only 1-4 percent of primary-care doctors, 21 percent of neurologists and 18 percent of patients interviewed indicated they are fairly or very pleased with the quantity of information available about clinical trials for Parkinson's infection. Discover further about  [http://www.visresearch.org/clinical-trials/investigator-finder-selection investigators finder]  by going to our impressive use with. &quot;People aren't getting the information they have to make decisions as to whether to be involved in a said Michael J. Fox. &quot;The less people that enter trials, the longer it will just take to develop new treatments.&quot; To meet this problem, the Parkinson's community has begun a fresh campaign, Advancing Parkinson's Therapies (APT), to be sure patients and physicians are better informed. The strategy seeks to handle information spaces and to offer doctors and patients with information on the number of clinical trials that are currently enrolling patients.